Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial.
Parlow S, Santo PD, Sterling LH, Goodliffe L, Motazedian P, Prosperi-Porta G, Morgan B, Koopman Z, Jung RG, Lepage-Ratte MF, Robinson L, Feagan H, Simard T, Wells GA, Kyeremanteng K, Ainsworth C, Amin F, Marbach JA, Fernando SM, Labinaz M, Belley-Cote EP, Hibbert B, Mathew R.
Parlow S, et al. Among authors: mathew r.
Am Heart J. 2023 Aug;262:83-89. doi: 10.1016/j.ahj.2023.04.010. Epub 2023 Apr 23.
Am Heart J. 2023.
PMID: 37094667
Clinical Trial.